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Abstract
Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer and 
accounts for approximately 75% of all cases of childhood leukemia. Both diagnostic 
and therapeutic advances have been instrumental in improving the outcomes of once 
a dreaded disease. Currently, approximately 90% of the children treated according 
to risk-directed and response-adapted therapy will be long-term survivors. The use 
of pediatric protocols for the treatment of adolescent and young adults (AYA) has 
also resulted in significant improvements in their long-term survival. New therapies 
including tyrosine kinase inhibitors (TKIs), monoclonal antibodies and CAR T-cell 
therapy are changing the approach to therapy for relapsed or refractory disease. We are 
approaching a time where therapy for all patients will be personalized with the use of 
genome-based characterization of disease and incorporation of drugs against action-
able targets, ultimately leading to improved clinical outcomes and decreased toxicity 
of therapy. Still, certain subgroups including patients with relapsed disease, infant 
ALL, and those with certain cytogenetic/molecular variants, remain challenging to 
treat. This chapter is an overview of the recent advances in the ALL disease biology, 
newly identified prognostic factors and an overview of emerging therapeutic options.
Keywords: acute lymphoblastic leukemia, minimal residual disease,  
CAR T-cell therapy, monoclonal antibody, advances
1. Background
ALL is the most common childhood malignancy and accounts for approximately 
30% of all childhood cancers and 75% of all cases of childhood leukemia [1, 2]. Each 
year, 3600 new cases of childhood ALL are diagnosed in the United States. Precursor 
B-ALL accounts for approximately 80–85% of the cases, while 15–20% are of the T-cell 
type [3]. The peak age group for ALL is 2–8 years, which accounts for approximately 
80% of the childhood ALL burden. The incidence decreases from 90 cases per million 
in the 2-8-year age group to 30 per million beyond 8 years of age [3, 4]. ALL is more 
common in children compared to older age groups as shown in Figures 1 and 2 [5].
The treatment of childhood ALL has evolved over the past 50 years. Successful 
development of multi-agent chemotherapy regimens, improved disease risk strati-
fication as well as enhanced supportive care have been instrumental in improving 
survival (Figure 3) [6]. The ALL chemotherapy backbone has included various 
phases—remission induction, central nervous system-directed therapy, interim 
maintenance and continuation therapy—with essentially the same chemotherapy 
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drugs in use since the 1960s. Modifications in dosing, mode of administration and 
varying combinations have resulted in improvements in outcomes now reaching a 
plateau [7–10]. Certain subgroups continue to have a very poor outcome, includ-
ing those patients with relapsed disease, infant ALL, and specific disease-related 
cytogenetic and molecular changes.
Childhood ALL differs from adult ALL in several ways. The overall survival 
(OS) of pediatric ALL has reached 90%, whereas adults still fare poorly at 
approximately 40% [10, 11]. Biologically, there is a higher frequency of poor 
prognostic subtypes like Philadelphia (Ph) positive and multi-lineage leukemia 
(MLL) rearranged leukemia in adults compared to children (7% vs. 1–2%) [12]. 
On the contrary, children have a higher frequency of favorable cytogenetics like 
hyperdiploidy and ETV6-RUNX1 as their leukemia drivers [12]. The majority of 
children with ALL are treated at specialized centres and as part of clinical tri-
als, unlike adults. Additionally, pediatric protocols have a greater dose intensity 
and deliver therapy guided by degree of myelosuppression. Adults generally 
tolerate treatment less well, resulting in increased treatment related toxicity 
Figure 1. 
Incidence of leukemia by age, SEER 1975–1999 [6].
Figure 2. 
Incidence of acute lymphoblastic leukemia by age and gender, SEER, 1975–1999 [6].
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[13]. The increased treatment related toxicity in adults could also be due to the 
increased use of stem cell transplant (SCT) in first remission, unlike the pediatric 
population where it is reserved only for high risk, poor responding or relapsed 
subgroups. Additionally, the use of pediatric-type protocols for the treatment 
of adolescent and young adults has resulted in significant improvements in their 
long-term survival [14, 15].
2. Minimal residual disease (MRD)-guided therapy
Minimal residual disease measured post-induction has been shown to be most 
predictive of long-term outcomes across various studies [16–18]. It is an amalgam 
of leukemia biology, patient factors as well as therapy. With the current protocol-
based, risk-directed therapy complemented by MRD based risk stratification, 
approximately 90% of the children aged 1–18 years are expected to be long-term 
survivors [19–22]. Various sensitive techniques have been utilized for evaluation of 
MRD including multi-color flow-cytometry (MFC), RT-PCR and next generation 
sequencing, which can detect 1 leukemic cell in 10,000–100,000 normal cells [16]. 
Analysis and tracking of Ig/TCR gene rearrangements by PCR is feasible in 90% of 
B and T-ALL and detection of fusion gene transcripts in approximately 30–40%. 
Other new techniques of MRD analysis include high-throughput sequencing (HTS) 
of Ig/TCR with a sensitivity of 1 in 1 million cells (10−6) [23]. In a recent study by 
Wood et al., HTS and MFC were comparable and HTS produced similar results as 
regards the prognostic significance of MRD [23]. Therapy modification based on 
MRD in the UKALL2003 and the Dutch ALL10 trial was associated with improved 
outcomes in childhood ALL [22, 24]. The AIEOP-BFM-ALL 2000 trial showed 
improved outcomes in both pediatric B and T ALL with MRD based therapy [25]. 
With the use of clinical and biological factors to stratify children with ALL into 
various risk groups, risk-directed therapy has led to the delivery of less intense as 
well as less toxic therapy to the low risk groups and more intensive therapy to those 
with a higher probability of relapse and poorer outcomes.
Despite high cure rates for pediatric ALL, up to 20% of the children will relapse. 
Re-induction for this group of patients yields remission in 79–90% of patients, 
Figure 3. 
Overall survival of children with acute lymphoblastic leukemia who were treated in the Children’s Cancer 
Group and Children’s Oncology Group trials between 1968 and 2009 (reprinted from Ref. [6], Copyright 
(2015) with permission from Massachusetts Medical Society).
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however long-term survival is only 40–50% [26, 27]. Moreover, the outcomes are 
worse in patients with primary refractory or relapse and refractory disease (r/r) 
as well as relapse post SCT; hence the unmet need for durable therapies for such 
children. The incorporation of newer therapies including monoclonal antibodies 
and Chimeric Antigen Receptor (CAR) T-cell therapy offer an alternative approach 
to the management of relapsed/refractory pediatric B ALL. The increasing use of 
upfront genome-based characterization of disease, and incorporation of drugs 
against identified actionable targets, will ultimately lead to improved clinical 
outcomes and deceased toxicity of therapy. This chapter will focus on the recent 
diagnostic and therapeutic advances which are changing the way children with ALL 
are treated.
3. Novel diagnostics in ALL
The recent WHO 2016 classification has incorporated morphological, immu-
nophenotypic and the existing cytogenetic features with the new molecular 
features associated with the various subgroups of ALL [28]. Cytogenetic/molecu-
lar abnormalities have been identified in 60–80% of patients with ALL using 
traditional methods [29]; however, with the advent of genome-wide analysis, 
this number is expected to increase. Evolution of the diagnostics from morphol-
ogy, immunohistochemistry, and banding techniques to genome-wide analysis 
and epigenomics has led to an increased appreciation of the biology of leuke-
mia. Genome-wide studies have also provided insight into the variation in the 
response to chemotherapy drugs among patients, explaining both the differences 
in toxicities and response to therapy [30]. In the near future, it can be envisioned 
that ALL will be molecularly characterized and defined, thus enabling us to 
deliver tailored therapy.
4. Existing and novel genomics of ALL
Cytogenetic aberrations in ALL have emerged as one of the most important 
prognostic factors driving the biology of the disease and patient outcomes [29]. 
Existing and recently identified novel prognostic markers are illustrated in Figure 4 
[31]. Children carrying either high hyperdiploidy (51–65 chromosomes) or ETV6-
RUNX1 as their cytogenetic drivers have an excellent prognosis with survival of 
>90% at 5 years. Adverse prognostic factors include t(9; 22), MLL translocation, 
t(17; 19), complex karyotype, low hypodiploidy (31–39 chromosomes), near 
haploidy (24–30 chromosomes), and near triploidy (60–78 chromosomes) [13]. 
Germline TP53 mutations are seen in children with ALL and low hypodiploidy 
(chromosomes 31–39) and confer a poor prognosis [32]. New additions to the list 
of adverse prognostic factors include BCR-ABL-1 like mutations, iAMP21, CRFL2 
overexpression, JAK mutations, and translocations involving immunoglobulin 
heavy chain (IGH), TCF-PBX1, IKZF1, PAX5, ERG and EBF1 mutations [31, 33–37]. 
Association of CDKN2A/2B deletions with Ph + ALL have emerged as a poor 
prognostic factor with guarded prognosis even with SCT [33]. FLT3 mutations have 
been found in KMT2A rearranged infant ALL and confer a poor prognosis [38–40]. 
Growing understanding of the biology of the disease allows better risk stratifica-
tion and in some cases alterations to therapy to improve outcomes. For example, 
therapy intensification has resulted in improved outcomes in children harboring the 
iAMP21 mutation [41, 42].
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In T-cell ALL, mutations commonly found are those involved in T-cell devel-
opment. Mutations of the NOTCH-1 activating gene are seen in approximately 
50–60% of all the T-ALL cases, while mutations involving the tumor suppressor 
gene FBXW7 are found in approximately 15% of cases [43]. The French group 
(FRALLE) has demonstrated favorable outcomes in those with NOTCH/FBXW7 
mutations along with wild-type PTEN/RAS [44]. However, the prognostic sig-
nificance of these in T-ALL is not well defined [45, 46]. Genome-wide association 
studies have recently identified a number of inherited genetic polymorphisms that 
are associated with an increased predisposition to develop ALL. These novel genes 
include ARID5B, GATA3, IKZF1, CDKN2A, CDKN2B, PIP4K2A and TP63 [47–53].
4.1 Novel genomics
Salient features of the novel prognostic factors are described below:
4.1.1 Ph-like ALL
BCR-ABL1-like ALL has recently been recognized by sequencing studies by the 
COG-St Jude consortium (TARGET) and the DCOG, and disease shows a similar 
gene expression profile to that of Ph + ALL in the absence of the BCR-ABL-1 gene 
translocation [54–56]. This accounts for 10% of pediatric and 15–20% of AYA 
ALL and confers an extremely poor prognosis with 5-year disease free survival 
(DFS) of 25% in AYA patients [34, 54]. The AALL0331 study showed decrease 
prevalence of Ph-like ALL in children with NCI standard risk (SR) compared to 
high risk (HR) ALL [57]. Ph-like ALL harbors two types of genomic alterations 
namely kinase activating and cytokine receptor alterations [58]. The kinase alterations 
which can be inhibited by ABL inhibitors include ABL1, ABL2, colony stimulating 
factor 1 receptor (CSF1R), platelet-derived growth factor receptor alfa and beta 
(PDGFRA, PDGFRB) [34]. Cytokine receptor alterations include alterations that 
act via the JAK/STAT pathway. This includes membrane-bound thymic stromal 
Figure 4. 
Sub-classification of childhood ALL. Blue wedges refer to B-progenitor ALL, yellow to recently identified 
subtypes of B-ALL, and red wedges to T-lineage ALL (reprinted from Ref. [31], copyright (2013) with 
permission from Elsevier).
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lymphopoietin receptor (TSLRP)/CRLF2. Other pathways involving CRLF2 
include PI3K and the mTOR pathways [58]. CRLF2 gene rearrangements have been 
associated with 50% of the cases of Ph-like ALL, of which another 50% also show 
positivity for JAK mutations [33, 56]. Additionally, IKZF1deletions (28%), EPOR, 
RAS pathway (10%) are also seen in this group. Patients harboring the CRLF2 
alterations fare poorly with high risk of relapse [59]. Similarly, increased expres-
sion of IKZF1 possibly translates into high post induction MRD as well as higher 
risk of relapse [60, 61].
4.1.2 IKZF1 deletions
The IKZF1 deletion has recently emerged as a novel genomic marker in child-
hood ALL. This subtype is commonly seen in older children, those with higher 
WBC counts, Down syndrome (DS), BCR-ABL and Ph-like ALL [55, 59, 62, 63]. 
Increased association is also seen with CRLF2 mutations [62]. IKZF1 deletion is an 
independent poor prognostic genomic feature in multivariate analysis [64–68]. The 
AIEOP-BFM group showed IKZF1 deletions confer a poor prognosis only in the high 
end-induction MRD group with co-existent CDKN2A, CDKN2B, PAX5, or PAR1 
mutations [69].
4.1.3 JAK-pathway mutations.
JAK mutations are commonly found in Ph-like ALL (20%) and are also associ-
ated with CRLF2 mutations [33]. These are also seen in approximately 15% of 
children with DS ALL [34, 70, 71]. Identification of this mutation is essential as it 
has therapeutic implications with responses seen both in vitro and in vivo to TKIs 
[72]. The ongoing phase II trial AALL1521 is testing upfront addition of ruxoli-
tinib to chemotherapy for CRFL2 rearranged or JAK-pathway mutant children 
with ALL [73].
4.1.4  Immunoglobulin heavy chain gene (IGH) rearrangement, CRLF2 
overexpression
IGH, a novel, adverse prognostic, cytogenetic driver is seen in less than 3% 
of pediatric and 10% of AYA ALL [74]. This rearrangement is characterized by 
the juxtaposition of a partner oncogene like CRLF2 (25%) or CEBP (10%) with 
IGH that drives the overexpression. CRLF2 overexpression is seen in a very high 
proportion (>50%) of children with DS, but the prognostic significance is still 
unclear [59].
4.1.5 iAMP21
This novel prognostic marker is seen in about 1.5–2% of pediatric ALL and is 
characterized by ≥3 extra copies of RUNX1 gene on a single abnormal chromo-
some 21q22 [75, 76]. Increased predisposition to develop iAMP21 ALL is seen 
in carriers of the Robertsonian translocation involving chromosomes 15 and 21 
[77]. This subtype presents in older children (median 10 years), is more com-
mon in females, and presents with WBC count of less than 50 × 109/L. Presence 
of this mutation confers a poor prognosis with standard therapy as well as high 
post remission-induction MRD [41, 78, 79]. However, the outcomes are better 
with MRD-guided and intensive chemotherapy, as shown in the UKALL2003 
and the ALL-BFM 2000 studies, hence precluding the need for SCT in first 
remission [41, 42].
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4.2 Treatment
4.2.1 Adolescents and young adults (AYA) with ALL
AYA constitutes a unique group of ALL with an age range of 15–39 years as 
defined by the NCI. Based on disease biology, there has always been a debate 
as to the best regimen to be used in this age group. Historically, ALL in the AYA 
population has been associated with a poor outcome and higher treatment related 
morbidity. However, the current focus of treating AYA as per pediatric protocols 
has resulted in improvement in their outcomes [14, 15] as shown in Table 1. 
Chemotherapy protocols similar to the BFM backbone with corticosteroids, 
vincristine and asparaginase in induction, post-remission asparaginase, and CNS 
prophylaxis during induction have shown improved survival in this cohort of 
patients. Also, SCT is offered only to the very-high risk population in first complete 
remission (CR1) [80].
To support this further, the excellent results from the large study by the 
GRAALL group have shown significantly improved survival (66% vs. 44%, 
P < 0.001) for those treated with pediatric-inspired protocols compared to histori-
cal controls treated with adult protocols [81]. The largest study which has evaluated 
this hypothesis is the US intergroup trial C10403, in which 318 AYA patients were 
treated as per the standard arm of the COG AALL0232 protocol. Encouraging 
results from this study showed a 2-year event free survival (EFS) of 66% and 
overall survival (OS) of 78%, with manageable toxicity profile and subsequently the 
NCI recommended that pediatric-inspired protocols could be used effectively up to 
the age of 40 years [82].
4.2.2 Philadelphia-chromosome positive ALL (Ph + ALL)
This high-risk group of ALL constitutes about 20–30% of the adult ALL and 3% 
of pediatric ALL [88]. Approximately 90% of the pediatric Ph + ALL have the p190 
translocation, which results from the translocation within the ‘minor’ breakpoint 
cluster region (mBCR) [89]. It is also characterized by a high frequency (66%) of 
deletions in B-cell development genes like IKZF1, PAX5, EBF1 and CDKN2A/B. 
[33, 88, 90]. Historically, outcomes were extremely poor with 5-year OS of 19% 
Serial no. Study group Patients numbers (n) Median age (y) Survival (%)
1. CCG [14] 197 16 67, OS 7y
2. CALGB [15] 124 19 46
3. FRALLE93 [15] 77 16 67 EFS
4. AIEOP [83, 84] 150 15 80, OS 2y
5. DCOG [85] 47 12 71 EFS
6. NOPHO92 [86] 36 16 74, OS 5y
7. MRC ALL [87] 61 15–17 71, OS 5y
8. UKALL2003 [24] 229 16–24 72 EFS
CCG, Children’s Cancer Group; CALGB, Cancer and Leukemia Group; FRALLE, French Acute lymphoblastic 
Leukemia Study Group; AIEOP, Associazione Italiana di Ematologia e Oncologia Pediatrica; DCOG, Dutch 
Childhood Oncology Group; NOPHO, Nordic Society for Pediatric Hematology and Oncology; MRC ALL, Medical 
Research Council (United Kingdom).
Table 1. 
Improved outcomes for AYA when treated according to pediatric-based protocols.
Advances in Hematologic Malignancies
8
without transplant and 35–45% with transplant in CR1. However, survival has 
drastically improved with the advent of TKIs as seen in the UKALLXII/ECOG2993 
study, 4-year OS with imatinib compared to historical cohort, 38% vs. 22% [91]. 
The AALL0031 reported excellent 5-year EFS of 70% ± 12% in patients treated with 
continuous imatinib and intensive chemotherapy compared with 31–39% for histor-
ical controls [92, 93]. Second generation TKIs are highly potent, demonstrate faster 
and deeper remissions, as well as increased CNS activity with an acceptable toxicity 
profile. The COG AALL0622 trial, did not show any survival advantage of dasatinib 
over imatinib when added to upfront chemotherapy backbone, 5-year OS 81% vs. 
86% for AALL0031 and AALL0622 respectively. In the same study, IKZF1 deletions 
were identified in 57% of cases and were associated with inferior outcomes [94].
Ph + ALL is no longer considered a subgroup for allogeneic SCT in CR1, and is 
reserved for poor responders or for relapsed disease. The AALL0031 study showed 
improved 3-year EFS equal to or better than sibling-related SCT (88% vs. 57%) for 
patients treated with imatinib and intensive systemic chemotherapy. Long-term 
follow-up data from the same study showed 5-year DFS of 70% in the imatinib plus 
chemotherapy group compared to SCT (65%-sibling donor, 59%-unrelated donor) 
[93]. The Korean Society of Adult Hematology working party showed similar 2-year 
molecular relapse-free survival in those not transplanted versus those transplanted 
(65% vs. 53%) [95]. In a study by Ravandi et al., achievement of negative MRD 
status was a significant prognostic factor regulating long-term survival. The 4-year 
OS rates were 66, 43 and 32% in patients with 3-month CMR, major molecular 
remission (MMR) and less than MMR, respectively [96]. Hence, adequate molecu-
lar response is the deciding factor for no SCT versus SCT.
With regards to the use of TKIs in the post-transplantation period, the consensus 
statement of the Acute Leukemia Working Party of the European Society for Blood 
and Marrow Transplantation, recommends patients with undetectable MRD post 
allogenic SCT may be either treated prophylactically or, may be monitored and 
treated pre-emptively with TKI if they have detectable MRD post-transplant. TKIs 
may be continued for a period of 12 months of continuous MRD negativity for 
those undergoing SCT in CR1, and continued indefinitely for those undergoing SCT 
in ≥2nd CR status [97]. Currently AALL1631, an international collaborative trial 
between the COG and the EsPhALL groups, is testing combination chemotherapy 
with imatinib in Ph + ALL. This randomized trial will assess survival and toxicity 
outcomes with less intensive therapy for those who are MRD negative post induc-
tion compared to the current EsPhALL and COG AALL1122 protocols. The role of 
post-transplant imatinib in the high-risk group of Ph + ALL undergoing SCT is also 
being evaluated [98].
4.2.3 Philadelphia-like ALL (Ph-like ALL)
Ph-like ALL constitutes a high-risk subtype of pediatric B ALL. Most studies 
demonstrate a poorer prognosis despite augmented traditional chemotherapy 
[54, 57, 70]. Interestingly, the Total XV study showed MRD directed therapy 
negated its poor prognosis [99]. Research is currently ongoing for a better under-
standing of the genomics of this group and we now know that this group harbors 
certain targetable genetic alterations. Potential targets and agents tested in pre-
clinical models include; CRLF2 inhibition (Givinostat [100], Luminespib [101], 
Selumetinib [102], TSLPR CART cells [103]), JAK-2 (CHZ868) [104], mTOR 
pathway (Rapamycin) [105], PI3K and mTOR pathways (Gedatolisib) [106], and 
TNF-a inhibition (Birinapant) [107]. These targets are now being prospectively 
studies in clinical trials across various centres. The MDACC trial in children 
older than 10 years is testing ruxolitinib or dasatinib with chemotherapy [108]. 
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Also, the phase II COG AALL1521 study is testing ruxolitinib with conventional 
chemotherapy in the age group of 1–21 years [109]. Another phase II trial from 
the NCI (COG AALL1131) in 1–30-year olds is testing dasatinib in combination 
with chemotherapy [110].
4.2.4 Hypodiploid ALL
Hypodiploidy (<45 chromosomes) is present in less than 5% of ALL. Survival 
across various studies ranges between 50 and 60% on currently available 
therapy [111–113]. Near haploid (24–30 chromosomes) and low-hypodiploidy 
(chromosome 31–39) fare poorly on current protocols with 5–8-year EFS of 
25–40% for near-haploid and 30–50% for low-hypodiploid ALL [111, 112, 114]. 
Interestingly, MRD has emerged as an important prognostic marker; improved 
long-term survival is seen in those with MRD negativity post induction com-
pared to MRD positive disease as shown by Mullighan et al. (85.1% vs. 44.4%) 
[115]. Recent studies show that children carrying pathogenic germline TP53 
mutations have a significantly higher incidence of hypodiploidy (65% vs. 1%), 
inferior EFS, OS and a very high chance of developing second cancers [92]. Also, 
a significantly large proportion (91.2%) of low hypodiploidy ALL is associated 
with germline TP53 mutation suggesting a possible association of hypodiploid 
ALL with Li-Fraumeni syndrome. In a study by Holmfeldt et al., near-haploid 
ALL was found to be associated with RAS-signaling, CREBBP, CDKN2A/B, 
PAG1 and IKZF3, and low hypodiploidy with P53, IKZF2, RB1, histone modifiers 
and CDKN2A/B [32, 116, 117]. The COG ALL03B1 showed no survival benefit 
from CR1 SCT. Interestingly, this was also true if children were MRD (>0.01%) 
positive pre-transplant [113]. Novel therapeutic approaches with emphasis on 
molecular targets could be the way forward in improving the outcomes of this 
high-risk subset of pediatric ALL.
4.2.5 Down syndrome ALL
Children with Down syndrome (DS) have an increased predisposition com-
pared to non-DS children to develop ALL with a cumulative risk of approximately 
2.1% by age of 5 years and 2.7% by age of 30 [118, 119]. Children with DS con-
stitute a very special group of pediatric ALL characterized by predominantly B 
immunophenotype and a marked absence of T immunophenotype. This group is 
neither associated with the favorable nor the unfavorable cytogenetic abnormali-
ties as seen in common pediatric ALL [120]. IKZF1 gene deletion, seen in approxi-
mately 35% of DS ALL portends inferior outcome [121, 122]. About 50–60% of the 
children with DS ALL harbor CRLF2 mutation, much higher than in children with 
ALL without DS (<10%). Approximately, 20% of children with DS ALL also carry 
JAK2 mutations, with majority also harboring CRLF2 mutation. However, their 
prognostic significance is unknown [121, 123, 124].
4.2.6 Infant ALL
This rare group comprises 2–4% of pediatric ALL and is characterized by high 
leukocyte count at diagnosis, bulky extramedullary disease, frequent CNS involve-
ment, and a poor prognosis [125, 126]. A relatively large proportion of these 
infants harbor the KMT2A gene on chromosome 11q23 in their malignant clone. 
[127, 128]. To date, approximately 94 different partner genes of KMT2A have been 
identified, with AF4 being the commonest [129]. These leukemia may contain 
FLT3 mutations (18%) and are characterized by overexpression of homeobox 
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(HOX) genes [130–133]. Younger age is associated with worse outcome. Despite 
intensified therapy across various trials groups including COG and Interfant, the 
5-year EFS remains poor (34–37%) in the KMT2A-rearranged infants [127, 128, 
134]. The role of SCT in CR1 remains controversial. Japanese and COG P9407 
studies have not shown any survival benefit with SCT compared to standard 
chemotherapy alone [134, 135]. The COG study AALL0631 failed to demonstrate 
any survival benefit with the upfront addition of lestaurtinib to the chemotherapy 
backbone, despite high levels of FLT3 expression [39, 136]. The COG pilot study 
AALL15P1, is evaluating the role of upfront addition of azacytidine in combination 
with standard chemotherapy (Interfant protocol) for epigenetic modification in 
KMT2A rearranged infant ALL [137].
4.2.7 T ALL
The outcomes for T ALL have been historically very poor, however with cur-
rent therapeutic approaches, outcomes are now comparable to those of B ALL with 
5-year EFS of 85% [138, 139]. MRD has emerged as the most important prognostic 
factor. Interestingly, kinetics of MRD clearance in T-ALL is slower than B-ALL, with 
late MRD negativity post-consolidation still translating into improved outcomes 
(7-year EFS, 80.6% ± 2.3%) [140]. The UKALL2003 and the AIEOP-BFM 2000 
trials have shown decreased relapse risk and survival benefit with the use of dexa-
methasone [138, 140]. Currently, the COG AALL1231 randomized trial is evaluating 
the role of bortezomib during induction and delayed intensification in patients with 
newly diagnosed T-cell ALL in the age group of 1–30 years using an augmented 
BFM-like backbone. Interestingly, this trial is also testing dexamethasone vs. pred-
nisolone during induction and the benefit of the addition of asparaginase during 
maintenance therapy. Increasingly, cooperative groups are moving away from the 
use of prophylactic cranial radiation or restricting its use to high risk disease or CNS 
3 status in upfront therapy [10, 11, 138, 141, 142]. The COG AALL1231 randomized 
trial is currently testing the safety of omitting prophylactic cranial irradiation in the 
non-high risk and non-CNS3 cases. The recent pilot AALL00P2 study tested upfront 
incorporation of nelarabine in newly diagnosed T ALL and has shown improved 
5-year EFS of 73% for all patients and 69% for those with slow early response [143]. 
The COG AALL0434 randomized study tested nelarabine in frontline therapy and 
demonstrated safety, however final results are awaited [144]. Allogenic SCT is cur-
rently reserved only for those with positive MRD post consolidation [145].
Relapse T-ALL still remains a therapeutic challenge as the salvage rates and 
OS are less than 25%. In the AALL01P2 study, out of 7 patients with relapsed 
T-ALL, only 2 achieved CR2 [146]. However, encouraging results from the 
AALL07P1 trial have shown CR2 of 68% by the addition of bortezomib to a 
4-drug re-induction regimen [147]. The focus is on optimizing upfront therapy 
to prevent relapse in the high-risk patients, with increasing efforts directed at 
developing effective salvage therapies for relapsed disease. Genomic sequencing 
studies have identified mutations related to various signaling pathways like JAK/
STAT, NOTCH, PI3K/Akt/mTOR and MAPK with emerging pre-clinical evi-
dence for targeted therapy [116, 148, 149]. Pre-clinical studies are also underway 
for the development of CD5 directed CAR T-cell therapy [117] as well as NK cell 
CARs against the T-ALL (personal communication from DiPersio and Rezvani).
4.2.8 Early T-precursor (ETP) ALL
ETP ALL has emerged as a new entity with increased heterogeneity at the 
molecular level. This subtype harbors NOTCH1 mutation at a much lower 
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frequency than T-ALL. It has a transcriptional profile similar to normal hemato-
poietic and myeloid stem cells [150]. Comparative genomic hybridization studies 
have shown absence of biallelic deletion of the TCR gamma locus (ABGD) and 
inferior outcomes with early treatment failure in this sub-group. [151, 152]. 
Other pathways implicated are the JAK/STAT, PI3K/Akt/mTOR, FLT3, and 
MAPK [153, 154]. Ruxolitinib, a JAK1/2 inhibitor has shown single-agent activity 
in pre-clinical studies [155]. There is emerging evidence that treatment on high 
risk regimens and MRD guided therapy leads to similar outcomes to those of 
standard T ALL [156, 157].
4.2.9 Immune-targeting in relapsed/refractory B-ALL
4.2.10 Role of monoclonal antibodies in paediatric ALL
The role of monoclonal antibodies against human differentiation antigens was 
first demonstrated by Kohler and Milstein using hybridomas with a goal of treat-
ment of hematological malignancies [158]. ALL is an excellent candidate for the 
incorporation of monoclonal antibody therapy due to a fairly constant lineage-spe-
cific antigen expression on the blasts and minimal expression of target antigen on 
normal tissues. Studies have demonstrated high remission rates with these agents, 
non-overlapping and manageable toxicity profiles leading to the FDA approval of 
these treatments for pediatric ALL. Monoclonal antibodies like blinatumomab and 
inotuzumab ozogamicin (InO) have shown excellent remission rates in pediatric 
ALL. The COG is currently evaluating antibodies like alemtuzumab, rituximab, 
blinatumomab, InO, and epratuzumab, both in r/r ALL as well as in newly diag-
nosed B-ALL in combination with standard chemotherapy, with a potential in 
future to be either incorporated with upfront therapy or replace certain components 
of standard of care chemotherapy.
4.2.11 Blinatumomab
Blinatumomab is a bi-specific T-cell engager antibody with binding sites to 
CD19 on B cells and to CD3 on T cells. Binding activates cytotoxic T cells, which 
induce cell death in the leukemic cell via the perforin system [159]. This drug is 
administered as a continuous infusion over 28 days and has shown acceptable 
activity and safety in various trials and was first FDA approved in December, 
2014 for use in r/r Ph negative ALL. Pioneering work by Topp et al. in a phase II, 
single-arm clinical trial showed that 80 % (16 of 20) of MRD positive patients 
became MRD negative post first cycle of blinatumomab [160]. Encouraging results 
from the BLAST trial, wherein 78% of the MRD positive patients became negative 
post one cycle of blinatumomab led to its FDA approval in MRD positive settings 
as well [161].
In a phase I/II trial in 70 children <18 years of age with r/r ALL who were 
treated with single agent blinatumomab, 39% (27) achieved CR and MRD 
negativity in 52% [162, 163]. The AALL1331 phase III randomized trial is test-
ing whether upfront addition of blinatumomab improves DFS in first relapse of 
ALL. In this trial all patients receive UK ALL R3 protocol for remission induc-
tion. Subsequently, the low risk group gets randomized to either control arm 
of R3 protocol or to receive three cycles of blinatumomab along with chemo-
therapy. The intermediate and the high-risk groups are randomized to either 
chemotherapy or two cycles of blinatumomab along with chemotherapy before 
proceeding to SCT. This trial is currently accruing patients and the results are 
awaited [164].
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4.2.12 Inotuzumab ozogamicin (InO)
InO is a monoclonal antibody against CD22 and conjugated to calicheamicin, 
a potent cytotoxic compound which binds to the DNA in the leukemic blasts, 
resulting in double-stranded DNA breaks and cell death via apoptosis [165]. It was 
FDA approved in August, 2017 for use in r/r ALL. In a phase II study in r/r ALL 
in the age group of 6–80 years, Kantarijian et al. demonstrated ORR of 57% with 
median OS of 6.7 months [166]. In phase III INO-VATE trial in relapsed adult B 
ALL, single agent InO showed superior outcome compared to standard chemo-
therapy with CR (81%) and 1-year OS (78%) [167] However, its use in pediatric 
population continues in development. A retrospective French study in children 
<18 years with r/r B-ALL showed promising results (CR 72%), with hepatic and 
hematologic toxicities [168]. Bhojwani et al. in r/r pediatric ALL showed high 
CR rate (67%) with MRD negativity, independent of cytogenetic subtype or 
prior lines of therapy [169]. The AALL1621 phase II randomized trial in the age 
group 1-21 years is evaluating the role of InO in children and young adults with r/r 
CD22+ B ALL [170].
4.2.13 CAR T-cell therapy: the new driving force for relapsed ALL
Relapsed or refractory ALL is one of the leading causes of childhood cancer 
mortality. Refractory ALL in particular has a dismal prognosis with significant 
chemotherapy resistance in the leukemic clone. The advent of CAR T-cell therapy 
has brought a paradigm shift in the management of children with highly resistant 
disease. Rosenberg et al. at the NCI pioneered the CAR T-cell therapy and demon-
strated successful treatment of cancer using CAR T-cells. This attractive therapy 
harnesses the immune system of the host to eradicate the leukemic clone. Adoptive 
T-cell therapy involves engineering T-cell receptors (TCRs) to bind to specific 
antigens present on tumor cells. These modified TCRs, known as CARs, allow the 
immune system to specifically target and destroy tumor cells in an MHC indepen-
dent manner, bypassing the immune escape mechanisms of downregulation of MHC 
class I antigens and altered antigen processing by tumor cells [171]. These modified 
T cells have the capacity to expand and proliferate in the host, produce cytokines to 
kill tumor cells, as well as cross blood-brain barrier as shown by Maude et al. [172].
Early results from ongoing trials have shown promising and durable responses. 
Current complete remission rate of 90% have been reported as per the CHP959 
phase I study [172]. The ELIANA [173] and ENSIGN [174] trials in r/r B ALL 
showed high CR rates of 90%, significantly higher than salvage rates of 30% 
attained with chemotherapy [26, 175]. This led to the FDA approval of CD19 4-1BB 
CAR T-cell therapy in August 2017 for children and young adults up to the age of 25 
years. Maude et al. showed durable remission and survival in children treated with 
CD19 CAR T cell therapy with EFS (50%) and OS (76%) at 12 months of follow-up 
[176]. Success from pediatric CAR T-cell therapy trials is driving research programs 
across ages and disease types worldwide. The advantage of this therapy is that it 
can be offered to patients who are ineligible for transplant or have relapsed post-
transplant, with a potential to ultimately replace SCT.
Tumor lysis syndrome, cytokine release syndrome and neurotoxicity are known 
complications of this therapy [177]. Another off-target toxicity is the development 
of B-cell aplasia, a surrogate for CAR T-cell persistence, results in agammaglobulin-
emia, and requires long-term immunoglobulin replacement [172]. With the use of 
CD19 directed CART cells, there is a risk of CD19 negative relapse [177]. Trials are 
underway to study the efficacy of CD22 CART cells as well as the use of dual CARS 
(CD19 + CD22).
13
Pediatric Acute Lymphoblastic Leukemia: Recent Advances for a Promising Future
DOI: http://dx.doi.org/10.5772/intechopen.87092
Author details
Sneha Tandon and Angela S. Punnett*
Division of Hematology/Oncology, The Hospital for Sick Children, University of 
Toronto, ON, Canada
*Address all correspondence to: angela.punnett@sickkids.ca
4.2.14 Liposomal drug formulations
The outcomes for pediatric ALL have significantly improved over the past five 
decades, and the focus is now on minimizing the toxicity and the late effects of che-
motherapy. Liposomal doxorubicin has shown remarkably low non-hematological 
toxicity, although the infection rates may be significant due to severe myelosuppres-
sion [178, 179]. In an attempt to decrease the toxicity of therapy, TACL 2012-002 
trial is testing the use of liposomal vincristine in children and AYA with relapsed 
ALL [180]. This study attempts to study the feasibility and safety of liposomal 
formulation of vincristine sulphate over standard vincristine in first, second or 
third relapse of B or T ALL.
5. Conclusions and future directions
Treatment of childhood ALL has evolved over the last 50 years with progress 
made both in the diagnostic and therapeutic arenas. A growing understanding of 
the biology of the disease has allowed better risk stratification and in some cases 
alterations to therapy to improve outcomes. Use of pediatric-type protocols in AYA 
ALL has improved outcomes. Break-through research leading to the development of 
CAR T-cell therapy, TKIs and monoclonal antibodies have brought a paradigm shift 
in the management of r/r B ALL. The medical community must now consider the 
significant cost of these therapies, with questions related to cost-effectiveness and 
resource allocation ripe for study. Long-term follow-up data for these revolutionary 
new cancer therapies are required. Outcomes for infant ALL and relapsed T ALL 
are still dismal and further research is needed to develop newer strategies to combat 
disease in these group of patients.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
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